Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
8.56B
Market cap8.56B
Price-Earnings ratio
-14.91
Price-Earnings ratio-14.91
Dividend yield
Dividend yield
Average volume
3.49M
Average volume3.49M
High today
$53.70
High today$53.70
Low today
$51.28
Low today$51.28
Open price
$53.33
Open price$53.33
Volume
2.57M
Volume2.57M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$40.03
52 Week low$40.03

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $52.45, giving the company a market capitalization of 8.56B. It carries a P/E multiple of -14.91.

As of 2026-08-02, Ionis Pharmaceuticals(IONS) stock has fluctuated between $51.28 and $53.70. The current price stands at $52.45, placing the stock +2.3% above today's low and -2.3% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 2.57M, against a daily average of 3.49M.

In the last year, Ionis Pharmaceuticals(IONS) shares hit a 52-week high of $86.74 and a 52-week low of $40.03.

In the last year, Ionis Pharmaceuticals(IONS) shares hit a 52-week high of $86.74 and a 52-week low of $40.03.

IONS News

Simply Wall St 3d
Ionis Pharmaceuticals Stock Slips As Revenue Drops And Losses Return - simplywall.st

...

Ionis Pharmaceuticals Stock Slips As Revenue Drops And Losses Return - simplywall.st
TipRanks 3d
Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating

Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Ionis Pharmaceuticals. The associated price target is $94.00. Unlock powerful investing to...

TipRanks 3d
Ionis Pharmaceuticals price target raised to $93 from $90 at BofA

BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $93 from $90 and keeps a Buy rating on the shares. The firm continues to see a favorable...

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More IONS News

TipRanks 4d
Ionis Expands Rare Disease Reach With Pediatric FCS Trial for Olezarsen

Ionis Pharmaceuticals Inc. (IONS) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, m...

TipRanks 4d
Ionis Pharmaceuticals reports Q2 EPS (69c), consensus (88c)

Reports Q2 revenue $268M, consensus $190.09M. “With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerid...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.